Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped up before the market opened on Thursday . The stock had previously closed at $11.22, but opened at $11.80. Santen Pharmaceutical shares last traded at $11.72, with a volume of 15,270 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Santen Pharmaceutical Trading Down 1.0%

The stock has a market capitalization of $3.79 billion and a P/E ratio of 0.10. The company has a fifty day simple moving average of $11.35 and a two-hundred day simple moving average of $10.92.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.